^
    10ms
    Multiplex In Situ Hybridisation for the Detection and Visualisation of OncoMasTR Target Gene Expression in Breast Cancer Tissue (EACR-AACR 2024)
    Conclusion The RNAscope ISH assay showed highly specific spatial localisation of UHRF1 and ZNF367 mRNA within intact tissue. Here, we have shown ISH-based quantitation of UHRF1 can be used to stratify early-stage breast cancer patients into low and high risk of recurrence.
    UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)
    |
    OncoMasTR test
    10ms
    Exploration of the Interplay between Master Transcriptional Regulators and Immune Cells within the Tumour Microenvironment of Breast Cancer (EACR-AACR 2024)
    Conclusion Tissue-based biomarkers with significant prognostic output were identified from the immune and OncoMasTR panels. A mIF panel incorporating both types of markers is being developed, aiming to offer improved prognostic prediction for early-stage breast cancer beyond current approaches.
    Immune cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    OncoMasTR test
    over1year
    The lack of documentation of patient's body mass index (BMI) in recent clinical trials (ESMO-BC 2023)
    Conclusions This study emphasizes that most drugs are given at fixed dose and the gap in knowledge we have on the efficacy of the novel anti-cancer treatments and the use of GEP and MS according to patient adiposity. As the prevalence of obesity is increasing worldwide, the evaluation of body composition is needed to increase knowledge on optimal use of drugs in clinical practice.
    Clinical • PARP Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • OncoMasTR test • Oncotype DX Breast Recurrence Score®Test
    over2years
    Exploration of the Prognostic Efficacy of a Combined OncoMasTR and Immune Marker Signature in Early Stage Breast Cancer Using Multiplex Immunofluorescence (EACR 2022)
    It showed significantly higher (HR=7; p<0.001) prognostic efficacy than the best performing model containing OncoMasTR and clinical markers only (HR=3.7; p=0.007). Conclusion This demonstrates the promise of a multiplex IHC biomarker panel containing both OncoMasTR and immune markers, potentially offering a better prognostic prediction for early-stage BC.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • TCF19 (Transcription Factor 19)
    |
    OncoMasTR test
    over2years
    Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer. (PubMed, Clin Chem)
    The OncoMasTR prognostic test displays robust analytical performance that is suitable for deployment by local pathology laboratories for decentralized use.
    Journal • Gene Signature
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • 6-gene signature
    |
    OncoMasTR test
    3years
    OncoMark acquired by US molecular diagnostic company, Cepheid Inc. (University College Dublin)
    "University College Dublin (UCD) today formally announced the acquisition of OncoMark Ltd, a UCD spin-out company, by US molecular diagnostics company, Cepheid Inc...OncoMark Ltd developed the OncoMasTR test, based on a panel of genetic drivers of breast cancer."
    M&A
    |
    OncoMasTR test
    over3years
    The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8. (PubMed, Clin Cancer Res)
    OncoMasTR Risk Score is highly prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0-3 involved lymph nodes. In combination with prior validation studies, this fully independent validation in ABCSG Trial 8 provides level 1B evidence for the prognostic capability of the OncoMasTR Risk Score.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR positive • ER positive + HER-2 negative
    |
    OncoMasTR test
    over3years
    Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. (PubMed, Eur J Cancer)
    Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification tool for identifying DR. A concise 6-gene signature with superior risk stratification was shown to increase prognosis reliability, which may help clinicians optimise treatment decisions.
    Journal • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • 6-gene signature
    |
    OncoMasTR test
    over4years
    [VIRTUAL] Master Transcription Regulators (MTRs) previously associated with breast cancer used to generate a prognostic model for biochemical recurrence after radical prostatectomy (EAU-I 2020)
    This analysis suggests that the breast cancer-derived OncoMasTR panel may also be prognostic for BCR after radical prostatectomy for prostate cancer and may add significant value to clinical information.
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin)
    |
    OncoMasTR test